Literature DB >> 20844041

Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner.

Leiyun Weng1, Yuichi Hirata, Masaaki Arai, Michinori Kohara, Takaji Wakita, Koichi Watashi, Kunitada Shimotohno, Ying He, Jin Zhong, Tetsuya Toyoda.   

Abstract

Hepatitis C virus (HCV) replication and infection depend on the lipid components of the cell, and replication is inhibited by inhibitors of sphingomyelin biosynthesis. We found that sphingomyelin bound to and activated genotype 1b RNA-dependent RNA polymerase (RdRp) by enhancing its template binding activity. Sphingomyelin also bound to 1a and JFH1 (genotype 2a) RdRps but did not activate them. Sphingomyelin did not bind to or activate J6CF (2a) RdRp. The sphingomyelin binding domain (SBD) of HCV RdRp was mapped to the helix-turn-helix structure (residues 231 to 260), which was essential for sphingomyelin binding and activation. Helix structures (residues 231 to 241 and 247 to 260) are important for RdRp activation, and 238S and 248E are important for maintaining the helix structures for template binding and RdRp activation by sphingomyelin. 241Q in helix 1 and the negatively charged 244D at the apex of the turn are important for sphingomyelin binding. Both amino acids are on the surface of the RdRp molecule. The polarity of the phosphocholine of sphingomyelin is important for HCV RdRp activation. However, phosphocholine did not activate RdRp. Twenty sphingomyelin molecules activated one RdRp molecule. The biochemical effect of sphingomyelin on HCV RdRp activity was virologically confirmed by the HCV replicon system. We also found that the SBD was the lipid raft membrane localization domain of HCV NS5B because JFH1 (2a) replicon cells harboring NS5B with the mutation A242C/S244D moved to the lipid raft while the wild type did not localize there. This agreed with the myriocin sensitivity of the mutant replicon. This sphingomyelin interaction is a target for HCV infection because most HCV RdRps have 241Q.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844041      PMCID: PMC2977884          DOI: 10.1128/JVI.00638-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins.

Authors:  Radhia Mahfoud; Nicolas Garmy; Marc Maresca; Nouara Yahi; Antoine Puigserver; Jacques Fantini
Journal:  J Biol Chem       Date:  2002-01-15       Impact factor: 5.157

2.  Kinetic analysis of C-terminally truncated RNA-dependent RNA polymerase of hepatitis C virus.

Authors:  Takahito Kashiwagi; Koyu Hara; Michinori Kohara; Kyoko Kohara; Jun Iwahashi; Nobuyuki Hamada; Haruhito Yoshino; Tetsuya Toyoda
Journal:  Biochem Biophys Res Commun       Date:  2002-02-01       Impact factor: 3.575

Review 3.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

4.  A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis.

Authors:  S Yasuda; H Kitagawa; M Ueno; H Ishitani; M Fukasawa; M Nishijima; S Kobayashi; K Hanada
Journal:  J Biol Chem       Date:  2001-09-06       Impact factor: 5.157

5.  Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment.

Authors:  Michel Lambot; Stéphanie Frétier; Anne Op De Beeck; Brigitte Quatannens; Sophie Lestavel; Veronique Clavey; Jean Dubuisson
Journal:  J Biol Chem       Date:  2002-04-05       Impact factor: 5.157

6.  RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells.

Authors:  Asako Murayama; Leiyun Weng; Tomoko Date; Daisuke Akazawa; Xiao Tian; Tetsuro Suzuki; Takanobu Kato; Yasuhito Tanaka; Masashi Mizokami; Takaji Wakita; Tetsuya Toyoda
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

7.  Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon.

Authors:  Takanobu Kato; Tomoko Date; Michiko Miyamoto; Akihiro Furusaka; Katsutoshi Tokushige; Masashi Mizokami; Takaji Wakita
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

8.  Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2.

Authors:  Stephanie T Shi; Ki-Jeong Lee; Hideki Aizaki; Soon B Hwang; Michael M C Lai
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture.

Authors:  Keril J Blight; Jane A McKeating; Joseph Marcotrigiano; Charles M Rice
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

10.  Caveolin-2 is targeted to lipid droplets, a new "membrane domain" in the cell.

Authors:  T Fujimoto; H Kogo; K Ishiguro; K Tauchi; R Nomura
Journal:  J Cell Biol       Date:  2001-03-05       Impact factor: 10.539

View more
  34 in total

Review 1.  Architecture and biogenesis of plus-strand RNA virus replication factories.

Authors:  David Paul; Ralf Bartenschlager
Journal:  World J Virol       Date:  2013-05-12

Review 2.  Lipids and RNA virus replication.

Authors:  Kouacou V Konan; Lorena Sanchez-Felipe
Journal:  Curr Opin Virol       Date:  2014-09-28       Impact factor: 7.090

3.  Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2.

Authors:  Irfan Khan; Divya S Katikaneni; Qingxia Han; Lorena Sanchez-Felipe; Kentaro Hanada; Rebecca L Ambrose; Jason M Mackenzie; Kouacou V Konan
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

4.  Hepatitis C Virus NS4B Can Suppress STING Accumulation To Evade Innate Immune Responses.

Authors:  Guanghui Yi; Yahong Wen; Chang Shu; Qingxia Han; Kouacou V Konan; Pingwei Li; C Cheng Kao
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

5.  Systems virology identifies a mitochondrial fatty acid oxidation enzyme, dodecenoyl coenzyme A delta isomerase, required for hepatitis C virus replication and likely pathogenesis.

Authors:  Angela L Rasmussen; Deborah L Diamond; Jason E McDermott; Xiaoli Gao; Thomas O Metz; Melissa M Matzke; Victoria S Carter; Sarah E Belisle; Marcus J Korth; Katrina M Waters; Richard D Smith; Michael G Katze
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.

Authors:  Kyoko Saito; Yoshitaka Shirasago; Tetsuro Suzuki; Hideki Aizaki; Kentaro Hanada; Takaji Wakita; Masahiro Nishijima; Masayoshi Fukasawa
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

Review 7.  Ultrastructural and biochemical basis for hepatitis C virus morphogenesis.

Authors:  Viviana Falcón; Nelson Acosta-Rivero; Sirenia González; Santiago Dueñas-Carrera; Gillian Martinez-Donato; Ivon Menéndez; Rocio Garateix; José A Silva; Emilio Acosta; Juan Kourı
Journal:  Virus Genes       Date:  2017-02-23       Impact factor: 2.332

8.  Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in Hepatitis C Virus RNA Replication Factories.

Authors:  Hossam Gewaid; Haruyo Aoyagi; Minetaro Arita; Koichi Watashi; Ryosuke Suzuki; Shota Sakai; Keigo Kumagai; Toshiyuki Yamaji; Masayoshi Fukasawa; Fumihiro Kato; Takayuki Hishiki; Ayako Mimata; Yuriko Sakamaki; Shizuko Ichinose; Kentaro Hanada; Masamichi Muramatsu; Takaji Wakita; Hideki Aizaki
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

9.  Host sphingomyelin increases West Nile virus infection in vivo.

Authors:  Miguel A Martín-Acebes; Enrique Gabandé-Rodríguez; Ana M García-Cabrero; Marina P Sánchez; María Dolores Ledesma; Francisco Sobrino; Juan-Carlos Saiz
Journal:  J Lipid Res       Date:  2016-01-13       Impact factor: 5.922

Review 10.  Hepatitis C Virus Replication.

Authors:  Keisuke Tabata; Christopher J Neufeldt; Ralf Bartenschlager
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.